» Journals » Ther Adv Med Oncol

Therapeutic Advances in Medical Oncology

Therapeutic Advances in Medical Oncology is a peer-reviewed journal that focuses on the latest advancements in the field of medical oncology. It provides a platform for researchers, clinicians, and healthcare professionals to share and discuss innovative therapeutic approaches, novel drug developments, and emerging treatment strategies for various types of cancer. The journal aims to enhance patient care and outcomes by promoting evidence-based practices and fostering collaboration among experts in the field.

Details
Abbr. Ther Adv Med Oncol
Start 2009
End Continuing
Frequency Bimonthly
p-ISSN 1758-8340
e-ISSN 1758-8359
Country United Kingdom
Language English
Specialty Oncology
Metrics
h-index / Ranks: 5296 68
SJR / Ranks: 1900 1529
CiteScore / Ranks: 2106 8.30
JIF / Ranks: 1632 4.9
Recent Articles
1.
Poulli T, Cortas C, Neokleous A, Tsappa I, Pilavaki P, Georgiou M, et al.
Ther Adv Med Oncol . 2025 Mar; 17:17588359251318863. PMID: 40040638
Follicular dendritic cell sarcoma (FDCS) is a rare sarcoma subtype, presenting as a relatively indolent disease in most cases. Given its rarity, clinicopathological characteristics and behavior as well as treatment,...
2.
Xie Y, Tao Z, Wang B, Zhao Y, Chen X, Li B, et al.
Ther Adv Med Oncol . 2025 Mar; 17:17588359251322291. PMID: 40034604
Background: Ferroptosis plays a vital role in cancer development and treatment. The relationship between ferroptosis-related genes and breast cancer prognosis, as well as immunotherapy outcomes, remains unknown. Objectives: To evaluate...
3.
Sang D, Su Y, Zhang Y, Guan Y, Fan S, Zhang J, et al.
Ther Adv Med Oncol . 2025 Mar; 17:17588359251318853. PMID: 40034603
Objective: Limited real-world efficacy and safety data exist regarding the use of trastuzumab deruxtecan (T-DXd) in the Chinese population with human epidermal growth factor receptor (HER2)-positive and HER2-low advanced breast...
4.
Gomez-Randulfe I, Lavender H, Symeonides S, Blackhall F
Ther Adv Med Oncol . 2025 Mar; 17:17588359251316988. PMID: 40026318
Therapeutic cancer vaccines aim to generate a robust immune response against tumour-associated antigens (TAAs) or tumour-specific antigens. While their safety is well established, their efficacy as monotherapy remains limited due...
5.
Fitzsimmons K, Fajardo M, Noor Z
Ther Adv Med Oncol . 2025 Feb; 17:17588359251322003. PMID: 40017901
We present a case report of a patient with metastatic small cell neuroendocrine carcinoma of the breast (SCNCB), a high-grade neuroendocrine triple-negative breast cancer, who achieved a complete response after...
6.
Coleman G, Wang Y
Ther Adv Med Oncol . 2025 Feb; 17:17588359251320736. PMID: 40017900
Chimeric antigen receptor T-cell (CART) therapy is an efficacious immunotherapy with known multi-organ toxicities, including gastrointestinal adverse events (GI-AEs). Eosinophilic colitis (EoC) is the inflammation of the intestine with diffuse...
7.
Abodunrin F, Olson D, Emehinola O, Bestvina C
Ther Adv Med Oncol . 2025 Feb; 17:17588359251320280. PMID: 40012708
Lung cancer is the leading cause of all cancer-related deaths in the United States and remains a global health challenge. While targeted therapy has revolutionized the treatment landscape of nonsmall...
8.
Liang X, Qin Y, Li P, Mo Y, Chen D
Ther Adv Med Oncol . 2025 Feb; 17:17588359251321904. PMID: 40012707
Currently, female breast cancer (BC) represents the highest incidence of cancer globally. This trend has raised significant attention regarding breast cancer young women (BCYW). With advancements in treatment technology, BCYW...
9.
Shimozaki K, Ooki A, Yoshino K, Tamba M, Udagawa S, Osumi H, et al.
Ther Adv Med Oncol . 2025 Feb; 17:17588359251322670. PMID: 40012706
Background: Although the emergence of immunotherapy has benefited patients with advanced gastric cancer (AGC), the magnitude of the benefit among real-world patients with HER2-negative AGC remains unclear. Objectives: The current...
10.
Cortiana V, Nadar S, Gambill J, Mahendru D, Theyver A, Coloma H, et al.
Ther Adv Med Oncol . 2025 Feb; 17:17588359251322290. PMID: 40008193
Oropharyngeal carcinoma, a type of head and neck cancer (HNC), is an emerging malignancy associated with low survival rates. It typically affects older males and correlates with smoking, drinking, and...